Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1α (HIF-1α)
- 4 December 2003
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 22 (55), 8948-8951
- https://doi.org/10.1038/sj.onc.1206995
Abstract
B-cell lymphoma gene (BCL-6) upregulation contributes to immortalization of mouse embryo fibroblast and primary B cells via upregulation of cyclin D1. As cyclin D1 overexpression is a common phenomenon in different cancers, BCL-6 protein overexpression may not be restricted to lymphomas. In this study, expression of BCL-6 was investigated by immunohistochemistry on paraffin-embedded specimens from 150 breast cancer patients and 10 specimens of normal breast tissue. The results showed BCL-6 overexpression (10% of cells) in 24/150 (16%) breast cancer patients, whereas in normal breast low expression (1 (r=0.197, P=0.016). Further, in 2 analyses, BCL-6-positivity was associated with overexpression of p53 (P=0.016), and hypoxia-inducible factor-1 (P<0.001). Involvement of BCL-6 in breast carcinogenesis is further underscored by comparative genomic hybridization analysis that showed gains at the BCL-6 locus (3q27) in 14/86 (16%) breast cancer tissues. The cases with amplification in BCL-6 showed an increased (25%) incidence of BCL-6 protein overexpression. Thus, this study is the first to show that BCL-6 oncogene activation plays a role in cancers other than lymphomas.Keywords
This publication has 16 references indexed in Scilit:
- Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsilHuman Pathology, 2003
- Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinomaCancer, 2003
- HIF-1 and tumor progression: pathophysiology and therapeuticsTrends in Molecular Medicine, 2002
- A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19ARF–p53 signalingGenes & Development, 2002
- Levels of Hypoxia-Inducible Factor-1 During Breast CarcinogenesisJNCI Journal of the National Cancer Institute, 2001
- Paraffin Immunoreactivity of CD10, CDw75, and Bcl-6 in Follicle Center Cell LymphomaLeukemia & Lymphoma, 2001
- Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factorsThe Journal of Pathology, 1998
- The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammationNature Genetics, 1997
- BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.Proceedings of the National Academy of Sciences of the United States of America, 1996
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991